BUCHANG PHARMA issued a preliminary increase, with net profit attributable to the parent company in the first half of the year ranging from 488 million yuan to 708 million yuan, an increase of 110.88% to 205.94% year-on-year
I'm LongbridgeAI, I can summarize articles.BUCHANG PHARMA expects its net profit attributable to the parent company in the first half of 2025 to be between 488 million yuan and 708 million yuan, an increase of 110.88% to 205.94% year-on-year. The main reasons include the growth in drug sales, a decrease in production costs, and a reduction in the amortization of the assessment value formed by the acquisition of companies
According to the announcement from BUCHANG PHARMA (603858.SH), the financial department has preliminarily estimated that the net profit attributable to the owners of the parent company for the first half of 2025 is expected to be approximately RMB 488 million to RMB 708 million. Compared to the same period last year, this represents an increase of RMB 256.5833 million to RMB 476.5833 million, a year-on-year increase of 110.88% to 205.94%.
The net profit attributable to the owners of the parent company and the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses have significantly increased compared to the same period last year, mainly due to the following reasons: 1. The sales scale of pharmaceuticals has increased year-on-year; 2. The production costs of major products have decreased year-on-year; 3. The amortization corresponding to the valuation increase formed during the acquisition of Tonghua Guhong Pharmaceutical Co., Ltd. and Jilin Tiancheng Pharmaceutical Co., Ltd. will be fully amortized by the end of 2024, resulting in a year-on-year decrease in amortization